Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0KK9E
|
|||
| Former ID |
DCL000110
|
|||
| Drug Name |
Exherin
|
|||
| Synonyms |
Exherin; 229971-81-7; UNII-B058ME29VU; ADH-1; ADH1; B058ME29VU; ADH 1; ADH-1 pepide; Exherin (ADH-1); ADH-1;ADH1;ADH 1; SCHEMBL13857500; CHEMBL3818130; ZINC3939935; ADH-10001; AKOS030526741; CS-3450; L-Cysteinamide, N-acetyl-L-cysteinyl-L-histidyl-l-alanyl-L-valyl-, cyclic (1-5)-disulfide; HY-13541
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Adherex Technol.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H34N8O6S2
|
|||
| Canonical SMILES |
CC1C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CN=CN2)NC(=O)C)C(=O)N)C(C)C
|
|||
| InChI |
1S/C22H34N8O6S2/c1-10(2)17-22(36)29-15(18(23)32)7-37-38-8-16(27-12(4)31)21(35)28-14(5-13-6-24-9-25-13)20(34)26-11(3)19(33)30-17/h6,9-11,14-17H,5,7-8H2,1-4H3,(H2,23,32)(H,24,25)(H,26,34)(H,27,31)(H,28,35)(H,29,36)(H,30,33)/t11-,14-,15-,16-,17-/m0/s1
|
|||
| InChIKey |
FQVLRGLGWNWPSS-BXBUPLCLSA-N
|
|||
| CAS Number |
CAS 229971-81-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neural cadherin (CDH2) | Target Info | Binder | [2], [3] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Panther Pathway | Cadherin signaling pathway | |||
| Wnt signaling pathway | ||||
| Pathway Interaction Database | Signaling events mediated by PTP1B | |||
| Posttranslational regulation of adherens junction stability and dissassembly | ||||
| N-cadherin signaling events | ||||
| FGF signaling pathway | ||||
| Reactome | CDO in myogenesis | |||
| Adherens junctions interactions | ||||
| WikiPathways | Primary Focal Segmental Glomerulosclerosis FSGS | |||
| BDNF signaling pathway | ||||
| Arrhythmogenic Right Ventricular Cardiomyopathy | ||||
| Neural Crest Differentiation | ||||
| Cell junction organization | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00264433) A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent. U.S. National Institutes of Health. | |||
| REF 2 | Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing soli... Ann Oncol. 2009 Apr;20(4):741-5. | |||
| REF 3 | Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Sep;26(7):587-612. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.